Overview An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia Status: Terminated Trial end date: 2008-04-01 Target enrollment: Participant gender: Summary Non-randomized, open, dose ranging and dose scheduling study of ascending doses of KW-2449 in subjects with AML, ALL, MDS and CML. Phase: Phase 1 Details Lead Sponsor: Kyowa Kirin Pharmaceutical Development, Inc.Kyowa Kirin, Inc.